Related Experiment Video

Updated: Aug 5, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

The effect of etophylline clofibrate on HDL subfractions

W Haberbosch, A Gnasso, W Ziegler

    Atherosclerosis
    |April 1, 1985
    PubMed

    Insights

    Etophylline clofibrate effectively improved lipid profiles in type II hyperlipoproteinemia patients. It increased high-density lipoprotein (HDL) components and significantly reduced low-density lipoprotein (LDL) cholesterol and very-low-density lipoprotein (VLDL) triglycerides.

    Area of Science:

    • Pharmacology
    • Lipid Metabolism
    • Cardiovascular Disease

    Background:

    • Type II hyperlipoproteinemia (HLP) is characterized by elevated levels of certain lipoproteins.
    • Effective management of HLP is crucial for reducing cardiovascular risk.

    Purpose of the Study:

    • To investigate the effects of etophylline clofibrate on lipoprotein metabolism in patients with type II HLP.
    • To assess changes in high-density lipoprotein (HDL) subfractions, very-low-density lipoproteins (VLDL), low-density lipoproteins (LDL), and lipolytic enzyme activities.

    Main Methods:

    • A 12-week treatment period with etophylline clofibrate (750 mg/day) in 14 type II HLP patients.
    • Study included washout and placebo periods, and patients followed a low-fat, low-cholesterol diet.
    • Measurements included lipids, apolipoproteins, and post-heparin lipolytic activities (PHLA) of lipoprotein lipase (LPL) and hepatic triglyceride lipase (HTGL).

    Main Results:

    • Etophylline clofibrate significantly increased HDL cholesterol and apoproteins, with distinct changes in HDL2 and HDL3 subfractions over time.
    • Significant reductions observed in plasma LDL cholesterol (19%) and VLDL triglycerides (22%).
    • VLDL-C apoproteins decreased by 31%, with a relative increase in apo C-II.

    Conclusions:

    • Etophylline clofibrate demonstrates a beneficial effect on lipid and apolipoprotein profiles in type II HLP.
    • The drug effectively lowers atherogenic lipoproteins and modulates HDL metabolism.
    • These findings suggest potential therapeutic value in managing dyslipidemias associated with HLP.

    More Related Videos

    Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia11:06

    Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

    Published on: April 7, 2023

    High-Density Lipoprotein-Specific Phospholipid Efflux Assay07:08

    High-Density Lipoprotein-Specific Phospholipid Efflux Assay

    Published on: September 30, 2025

    Related Concept Videos

    First Pass Effect01:12

    First Pass Effect

    Presystemic elimination, or the first-pass effect, is the metabolism of drugs that reduces their effective concentration at the site of action. Apart from the first-pass effect, the systemic bioavailability of the drug is also reduced by other factors, including incomplete absorption or chemical degradation of drugs.
    Depending on the route of administration, drugs can be metabolized in the liver, intestine, lungs, and vasculature. Orally administered drugs are first absorbed through the...
    Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents

    Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

    Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
    Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

    Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

    In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

    In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
    Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

    Blood Studies for Cardiovascular System III: Serum Lipid Profile

    Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
    Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
    Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...